Pfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for ...
Hosted on MSN9d
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 SalesKey Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...
Pfizer Inc. has announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination ...
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...
The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.
Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.
Sasanlimab (PF-06801591) added to BCG therapy significantly improved outcomes for patients with BCG-naive, high-risk ...
Pfizer is preparing to discuss the trial outcomes with worldwide health authorities, which could support potential regulatory filings. Credit: © 2024 Pfizer Inc ...
President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback